Host: Debi Wimberley, Founder of the Effective Cannabis Newsletter and Certified Medical Cannabis Educator

Guest: Dr. Shiksha Gallow

When most people hear the words “cancer research,” they think about tumor size, survival rates, and biomarkers. But for Dr. Shiksha Gallow, a leading Cannabis clinician and research principal investigator at the University of Pretoria, the real question is much more human.

How is the Patient Actually Living With Cancer?

In this episode of Effective Cannabis Conversations, Dr. Gallow shares groundbreaking insights from her newly completed scoping review and clinical study on cannabinoids and prostate cancer. Her work doesn’t just look at cancer cells in a lab. It looks at real men sitting in real clinics, navigating pain, sleep disruption, emotional distress, and the daily reality of living with advanced disease.

This conversation marks a shift in how we think about cancer care, from disease-centered to human-centered, and it highlights the growing role of the Endocannabinoid System (ECS) in integrative oncology.

Why This Research Was Needed

Dr. Gallow’s research began with a simple but uncomfortable pattern.

Men with prostate cancer were being tracked meticulously by numbers: PSA values, Gleason scores, imaging scans. But no one was asking the questions that actually define quality of life:

• Are you sleeping?

• Are you in pain?

• Can you function in your relationships?

• Do you feel emotionally supported?

At the same time, many of these men were already using Cannabis privately for pain, anxiety, and sleep, often without telling their oncologists out of fear or stigma.

What Dr. Gallow discovered in the literature was equally troubling. While preclinical studies showed cannabinoids interacting with cancer pathways, almost no clinical research focused on patient-centered outcomes.

In other words, science was studying tumors, but ignoring people.

Inside the Clinical Study: 90 Men, Three Treatment Groups

To bridge this gap, Dr. Gallow designed a real-world clinical study involving 90 men with advanced prostate cancer, divided into three groups:

• Chemotherapy only

• Cannabis only

• Cannabis plus chemotherapy

Her study measured both traditional oncology outcomes and human outcomes, including:

• Pain intensity and pain interference

• Emotional well-being and anxiety

• Sleep quality

• Self-care and daily functioning

• PSA levels

• PET/CT tumor imaging

This design placed Cannabis not as an alternative to oncology, but as a potential adjunct within integrative cancer care.

What the Study Found: Pain, Mood, and Sleep Improved

The most consistent and clinically meaningful findings came from the symptom and quality-of-life data.

Men in both Cannabis groups, especially those using Cannabis alongside chemotherapy, experienced:

• Greater reductions in pain

• Less breakthrough pain

• Improved emotional well-being

• Better sleep continuity

• Less distress and overwhelm

Many patients reported that Cannabis “took the edge off,” allowing them to process their diagnosis with more calm and resilience.

This didn’t mean the cancer disappeared. But it meant they were able to live inside their treatment, not just endure it.

We didn’t ask what Cannabis does to cancer. We asked what Cannabis does to the man who has the cancer.

Dr. Shiksha Gallow

PSA and Imaging: What Happened to the Tumors?

From a biomedical perspective, the study revealed nuanced but important findings.

PSA levels declined faster in Cannabis-containing groups, although final PSA values were similar across all groups.

The Cannabis plus chemotherapy group showed a higher likelihood of tumor reduction and remission on PET/CT imaging.

This suggests a possible synergistic effect, where cannabinoids may enhance how the body responds to conventional treatments.

Importantly, Cannabis did not worsen cancer markers or interfere with chemotherapy outcomes.

Safety Matters: What Didn’t Happen

One of the most critical findings was what did not occur.

Across the study, there was no evidence of:

• Harmful drug interactions

• Worsening chemotherapy side effects

• Liver, kidney, or blood abnormalities

• Increased hospitalizations

• Serious psychiatric or cardiac events

In clinical terms, Cannabis was well-tolerated and did not compromise oncology care.

This is a major message for skeptical clinicians. Patients are already using Cannabis. The real risk lies in silence, secrecy, and lack of supervision.

The Real Gap in Cancer Care

Dr. Gallow’s work exposes a deeper issue in modern healthcare.

Patients are moving through cancer systems that prioritize efficiency over humanity, protocols over conversations, and survival over quality of life.

The Endocannabinoid System offers a missing biological framework for addressing this gap. It plays a central role in:

• Pain regulation

• Immune modulation

• Stress response

• Sleep cycles

• Emotional balance

Yet the ECS is still absent from most medical education and oncology protocols.

What This Means for Patients and Providers

This research does not claim Cannabis cures cancer.

What it does show is that Cannabis may help patients live better with their diagnosis, with less pain, more emotional stability, better sleep, and greater daily function.

For patients:

• Do not self-medicate in isolation.

• Do not replace standard care.

• Do seek supervised, informed guidance.

For providers:

• Ask and be open about Cannabis use.

• Understand ECS-based mechanisms.

• Collaborate with cannabinoid-trained clinicians.

• Practice harm reduction and shared decision-making.

Integrative oncology is not about choosing between treatments. It’s about building bridges between them.

The Future of Integrative Oncology

Dr. Gallow is building a long-term research arc focused on evidence-based complementary cancer care. Her goal is not to disrupt oncology, but to expand it.

She envisions a future where:

• Cannabinoid therapies are discussed openly

• Quality of life is a core treatment outcome

• The Endocannabinoid System is taught in medical schools

• Cancer care becomes both scientific and humane

• Not just about living longer, but about living better.

Since this conversation was recorded, we’ve learned that Dr. Gallow’s research has been approved and is now in the final stages of publication. To receive a notification when the research paper is released, email [email protected]

About Dr. Shiksha Gallow:

Dr. Shiksha Gallow is a globally recognized pioneer in medical Cannabis research and clinical application. She was awarded first prize by the South African Medical Association (SAMA) for her groundbreaking work on medical Cannabis and prostate cancer, marking a significant advancement in evidence-based cannabinoid medicine. As the Medical Director of the Holistic Integrative Healing Institute and Principal Investigator of South Africa’s first Medical Cannabis Study, Dr. Gallow has become an internationally sought-after expert, speaking at leading medical and scientific conferences across the United States, Europe, and Asia. Her work bridges rigorous science, patient-centered care, and global health innovation, positioning her as a leading voice shaping the future of medical Cannabis.

Check out:

Website

LinkedIn

About Debi Wimberley:

Debi Wimberley is a resilient advocate for Medical Cannabis education and self-empowered health. A survivor of decades of chronic pain and lung disease, she turned her background in medical technology, oncology, and hospital systems into tools for thriving. Certified in Medical Cannabis applications and Patient Care, Debi is a professional communicator, podcaster, TEDx speaker, and author. Founder of Effective Cannabis and Effective Cannabis Newsletter. Her mission is to centralize high-quality, accurate, fact-based education through collaboration with other certified Cannabis educators, health coaches, and professionals.

Click the Learn More Button to Subscribe to the Effective Cannabis YouTube Channel